UPDATE: Due to the high circulation of the SARS-CoV-2 Omicron variant, REGEN-COV is not currently authorized for use in any U.S. Region. Please refer to the authorized Fact Sheet and FDA statement for additional details.
Learn More
Skip to content

INVESTIGATIONAL PIPELINE A POWERFUL RESEARCH AND DEVELOPMENT ENGINE

PIPELINE & MEDICINES

INVESTIGATIONAL PIPELINE

Our pipeline is powered by end-to-end research and development capabilities. The Research team discovers promising new drug compounds. From there, Global Development brings these investigational candidates through the full clinical development process, from trial design to study execution and lifecycle management. Our product portfolio reflects the true collaborative spirit of Regeneron.

Explore the Regeneron clinical pipeline

Select therapeutic area(s):
Select phase(s):
Select collaborator(s):

Displaying item

Clear Filters

Phase 1

  • ALN-APP1
    APP RNAi Therapeutic Early-onset Alzheimer’s disease
    General Medicine
  • ALN-HSD1
    HSD17B13 RNAi Therapeutic Nonalcoholic steatohepatitis
    Immunology & Inflammation General Medicine
  • FIANLIMAB
    LAG-3 Antibody Solid tumors, advanced hematologic malignancies
    Oncology Hematology
  • Next Generation Covid-19 Antibodies
    Antibodies to SARS-CoV-2 Variants Healthy volunteers
    Infectious Diseases General Medicine
  • NTLA-20013
    CRISPR/Cas9 Transthyretin (ATTR) amyloidosis
    Rare Diseases Hematology
  • ODRONEXTAMAB
    CD20 X CD3 Antibody Certain B-cell malignancies
    Oncology Hematology
  • UBAMATAMAB (REGN4018)
    MUC16 X CD3 Antibody Platinum-resistant ovarian cancer
    Oncology
  • REGN4336
    PSMA X CD3 Antibody Prostate cancer
    Oncology
  • REGN5093
    MET X MET Antibody MET-altered advanced non-small cell lung cancer (NSCLC)
    Oncology
  • REGN5093-M114
    MET X MET Antibody MET overexpressing advanced cancer
    Oncology
  • REGN5381/REGN9035
    Agonist Antibody to NPR1/Reversal Agent to REGN5381 Reversal agent in healthy volunteers
    Cardiovascular & Metabolic Diseases General Medicine
  • REGN5458
    BCMA X CD3 Antibody Multiple myeloma
    Hematology
  • REGN5459
    BCMA X CD3 Antibody Transplant desensitization in patients with chronic kidney disease
    Oncology Hematology
  • REGN5668
    MUC16 x CD28 Antibody Platinum-resistant ovarian cancer
    Oncology
  • REGN5678
    PSMA X CD28 Antibody Prostate cancer
    Oncology
  • REGN6569
    GITR Antibody Solid tumors
    Oncology
  • REGN7257
    IL-2Rg Antibody Aplastic anemia
    Hematology
  • REGN7075
    EGFR x CD28 Antibody Solid tumors
    Oncology
  • REGN9933
    Factor XI Antibody Thrombosis
    Hematology

Phase 2

  • CEMIPLIMAB
    PD-1 Antibody Metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), neoadjuvant CSCC, second-line cervical cancer ISA101b combination
    Oncology
  • CEMDISIRAN1
    C5 siRNA Therapeutic Immunoglobulin A nephropathy
    Rare Diseases Hematology
  • DUPILUMAB5
    IL-4R Antibody Grass allergy
    Immunology & Inflammation
  • GARETOSMAB
    Activin-A Antibody Fibrodysplasia ossificans progressiva (FOP)
    Rare Diseases General Medicine
  • ODRONEXTAMAB
    CD20 X CD3 Antibody B-cell non-Hodgkin lymphoma
    Cardiovascular & Metabolic Diseases Oncology
  • POZELIMAB
    C5 Antibody CD55-deficient protein-losing enteropathy
    Rare Diseases Hematology
  • MIBAVADEMAB (REGN4461)
    LEPR Agonist Antibody Generalized lipodystrophy, partial lipodystrophy
    Cardiovascular & Metabolic Diseases Rare Diseases General Medicine
  • REGN5381/REGN9035
    Agonist Antibody to NPR1/Reversal Agent to REGN5381 Heart failure
    General Medicine
  • REGN5458
    BCMA X CD3 Antibody Multiple myeloma
    Oncology Hematology
  • SARILUMAB5
    IL-6R Antibody Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis
    Immunology & Inflammation
  • VIDUTOLIMOD
    TLR9 Immune Activator CSCC and Merkel cell carcinoma
    Oncology

Phase 3

  • AFLIBERCEPT 8MG2
    VEGF-Trap Wet age-related macular degeneration (AMD), diabetic macular edema (DME)
    Ophthalmology
  • AFLIBERCEPT2
    VEGF-Trap Retinopathy of prematurity (ROP)
    Ophthalmology
  • ALIROCUMAB
    PCSK9 Antibody Heterozygous familial hypercholesterolemia (HeFH) in pediatrics
    Cardiovascular & Metabolic Diseases General Medicine
  • CEMIPLIMAB
    PD-1 Antibody First-line non-small cell lung cancer (NSCLC) chemo combination, second-line cervical cancer, adjuvant CSCC
    Oncology
  • DUPILUMAB5
    IL-4R Antibody Eosinophilic esophagitis (EoE) in pediatrics; chronic obstructive pulmonary disease (COPD); bullous pemphigoid; chronic spontaneous urticaria; prurigo nodularis; allergic bronchopulmonary aspergillosis; chronic inducible urticaria - cold; chronic rhinosinusitis without nasal polyposis; allergic fungal rhinosinusitis; chronic pruritis of unknown origin
    Immunology & Inflammation
  • FASINUMAB6
    NGF Antibody Osteoarthritis pain of the knee or hip
    Pain/Neurology General Medicine
  • FIANLIMAB
    LAG-3 Antibody first-line metastatic melanoma
    Oncology
  • ITEPEKIMAB5
    IL-33 Antibody Chronic obstructive pulmonary disease (COPD)
    Immunology & Inflammation
  • POZELIMAB + CEMDISIRAN1
    C5 Antibody + C5 siRNA Therapeutic Myasthenia gravis, paroxysmal nocturnal hemoglobinuria
    Cardiovascular & Metabolic Diseases Rare Diseases
  • REGN1908-1909
    Fel d 1 Multi-Antibody Therapy Cat allergy
    Immunology & Inflammation
  • REGN5713-5714-5715
    Bet v 1 Multi-Antibody Therapy Birch allergy
    Immunology & Inflammation

No results found. Please adjust your filter selection and try again.

1In collaboration with Alnylam

2In collaboration with Bayer outside of the U.S.

3In collaboration with Intellia

4In collaboration with Roche outside of the U.S.

5In collaboration with Sanofi

6In collaboration with Teva and Mitsubishi Tanabe outside of the U.S.

7In collaboration with Ultragenyx outside of the U.S.

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

Pipeline last updated:

Scientific trailblazers

Following the science leads to unexpected breakthroughs and diverse areas of study —from ophthalmology to cancer to inflammation to pain to cardiovascular disease.

Our Current Research

Discover our clinical trials

Learn more about our clinical trials and find one near you.

Find Trials

Back
to top